GlassScriptPhysician profile
Farah Mamedov
NPI 1063467439
$1,873.67
in general payments reported to CMS, 2019-2025
26 companies · $414 in 2025
The $414 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $160 · 2021: $242 · 2022: $280 · 2023: $141 · 2024: $388 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $283.33 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $180.23 | 2019-2024 | |
| Pfizer INC. | $153.61 | 2019-2024 | |
| Cranial Technologies, INC | $144.91 | 2019-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $138.11 | 2024-2025 | |
| Organon LLC | $124.40 | 2025 | Vtama |
| Ironshore Pharmaceuticals INC. | $100.17 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $92.37 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $88.37 | 2023-2024 | Ycanth |
| Seqirus USA INC | $83.52 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $74.52 | 2020-2022 | |
| Neos Therapeutics, LP | $67.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.13 | 2019-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Alk-Abello, INC | $53.38 | 2023-2025 | Neffy, Odactra |
| Adlon Therapeutics L.P. | $32.50 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $26.15 | 2019 | |
| Genentech USA, INC. | $25.98 | 2020 | |
| Sobi, INC | $24.89 | 2021 | |
| Biomarin Pharmaceutical INC. | $22.00 | 2024 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $20.53 | 2023 | Flumist Quadrivalent |
| Jazz Pharmaceuticals INC. | $18.82 | 2019 | |
| Tris Pharma INC | $15.10 | 2020 | |
| Neurocrine Biosciences, INC. | $14.87 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.56 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Mamedov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.